Fig. 5From: Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatmentEffect of cisplatin and ACY-1083 on markers of synaptic integrity. Brains were collected after completion of all behavioral tests and processed for immunofluorescence analysis of synaptophysin and PSD95 in the CA1 and DG regions of the hippocampus. Mean fluorescence intensity was quantified. a–d, q Example images and quantification for synaptophysin staining in CA1 region from mice treated with (a) PBS + vehicle, (b) cisplatin + vehicle, (c) PBS + ACY-1083, or (d) cisplatin + ACY-1083 (n = 7; two-way ANOVA with Tukey’s post-hoc analysis: F (1, 24) = 7.169; PBS vs. Cisplatin, p = 0.0005; Cisplatin vs. Cisplatin + ACY-1083, p < 0.0001). e–h, r Example images and quantification for synaptophysin staining in DG region from mice treated with (e) PBS + vehicle, (f) cisplatin + vehicle, g PBS + ACY-1083, or (h) cisplatin + ACY-1083 (n = 7; two-way ANOVA with Tukey’s post-hoc analysis: F (1, 24) = 15.97; PBS vs. Cisplatin, p < 0.0001; Cisplatin vs. Cisplatin + ACY-1083, p < 0.0001). i–l, s Example images and quantification for PSD95 staining in CA1 region from mice treated with (i) PBS + vehicle, (j) cisplatin + vehicle, (k) PBS + ACY-1083, or (l) cisplatin + ACY-1083 (n = 7; two-way ANOVA with Tukey’s post-hoc analysis: F (1, 24) = 5.554; PBS vs. Cisplatin, p = 0.0138; Cisplatin vs. Cisplatin + ACY-1083, p = 0.0434). m–p, t Example images and quantification for PSD95 staining in DG region from mice treated with (m) PBS + vehicle, (n) cisplatin + vehicle, (o) PBS + ACY-1083, or (p) cisplatin + ACY-1083 (n = 7; two-way ANOVA with Tukey’s post-hoc analysis: F (1, 24) = 7.052; PBS vs. Cisplatin, p = 0.0065; Cisplatin vs. Cisplatin + ACY-1083, p = 0.0275). Results are expressed as means ± SEM; *P < 0.05, **P < 0.01Back to article page